NRAS and melanoma: For example, our finding that the MEK inhibitor Cobi used as a single agent can inhibit the lytic capacity of T cells might be of importance in studies using MEKi without BRAFi in the setting of melanoma with non-mutated BRAF but mutated NRAS [20].